# Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

> **NCT00002192** · PHASE2 · COMPLETED · sponsor: **Anderson Clinical Research**

## Conditions studied

- Mycobacterium Avium-Intracellulare Infection
- HIV Infections

## Interventions

- **DRUG:** Rifapentine
- **DRUG:** Ethambutol hydrochloride
- **DRUG:** Clarithromycin
- **DRUG:** Azithromycin

## Key facts

- **NCT ID:** NCT00002192
- **Lead sponsor:** Anderson Clinical Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002192, "Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00002192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*